Sanofi gets Dupixent approved for the treatment of COPD in the EU
In the US, Sanofi expects a response by September 27.
by MARKETWIRE
Sanofi has received approval in Europe for the treatment of chronic obstructive pulmonary disease, COPD, with type 2 inflammation and chronic bronchitis, according to a stock exchange announcement.
Dupixent is already approved for the treatment of several conditions such as asthma and skin diseases, and last year alone sold for EUR 10.7bn, according to Bloomberg News.
The US Food and Drug Administration is also reviewing an application for Dupixent for the treatment of COPD. Sanofi expects a response by September 27 at the latest.
English edit: Catherine Brett
Related articles
CHMP recommends 14 new medications for approval
For subscribers
